登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，12月4日，Correlates of protection against SARS-CoV-2 in rhesus macaques》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-12-23

  • Correlates of protection against SARS-CoV-2 in rhesus macaques
    Katherine McMahan, Jingyou Yu, […]Dan H. Barouch
    Nature (2020)

    Abstract
    Recent studies have reported protective efficacy of both natural immunity1 and vaccine-induced immunity2–7 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge in rhesus macaques. However, the importance of humoral and cellular immunity for protection against SARS-CoV-2 infection remains to be determined. Here we show that adoptive transfer of purified IgG from convalescent macaques protects naïve recipient rhesus macaques against SARS-CoV-2 challenge in a dose dependent fashion. Depletion of CD8+ T cells in convalescent animals partially abrogated the protective efficacy of natural immunity against SARS-CoV-2 re-challenge, suggesting the importance of cellular immunity in the context of waning or subprotective antibody titers. These data demonstrate that relatively low antibody titers are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may also contribute to protection if antibody responses are suboptimal. We also show that higher antibody titers are required for therapy of SARS-CoV-2 infection in macaques. These findings have important implications for the development of SARS-CoV-2 vaccines and immune-based therapeutics.

  • 原文来源：https://www.nature.com/articles/s41586-020-03041-6
138浏览量
原文链接
相关报告

  • 《Science，5月20日，SARS-CoV-2 infection protects against rechallenge in rhesus macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-21
    • SARS-CoV-2 infection protects against rechallenge in rhesus macaques View ORCID ProfileAbishek Chandrashekar1,*, View ORCID ProfileJinyan Liu1,*, View ORCID ProfileAmanda J. Martinot1,2,*, View ORCID ProfileKatherine McMahan1,*, View ORCID ProfileNoe B. Mercado1,*, View ORCID ProfileLauren Peter1,*, View ORCID ProfileLisa H. Tostanoski1,*, View ORCID ProfileJingyou Yu1,*, View ORCID ProfileZoltan Maliga3, Michael Nekorchuk4, View ORCID ProfileKathleen Busman-Sahay4, View ORCID ProfileMargaret Terry4, View ORCID ProfileLinda M. Wrijil2, View ORCID ProfileSarah Ducat2, David R. Martinez5, View ORCID ProfileCaroline Atyeo3,6, View ORCID ProfileStephanie Fischinger6, View ORCID ProfileJohn S. Burke6, View ORCID ProfileMatthew D. Slein6, View ORCID ProfileLaurent Pessaint7, View ORCID ProfileAlex Van Ry7, View ORCID ProfileJack Greenhouse7, View ORCID ProfileTammy Taylor7, View ORCID ProfileKelvin Blade7, Anthony Cook7, View ORCID ProfileBrad Finneyfrock7, Renita Brown7, Elyse Teow7, Jason Velasco7, View ORCID ProfileRoland Zahn8, View ORCID ProfileFrank Wegmann8, View ORCID ProfilePeter Abbink1, View ORCID ProfileEsther A. Bondzie1, View ORCID ProfileGabriel Dagotto1,3, View ORCID ProfileMakda S. Gebre1,3, Xuan He1, View ORCID ProfileCatherine Jacob-Dolan1,3, View ORCID ProfileNicole Kordana1, Zhenfeng Li1, View ORCID ProfileMichelle A. Lifton1, View ORCID ProfileShant H. Mahrokhian1, View ORCID ProfileLori F. Maxfield1, View ORCID ProfileRamya Nityanandam1, View ORCID ProfileJoseph P. Nkolola1, View ORCID ProfileAaron G. Schmidt6,9, View ORCID ProfileAndrew D. Miller10, View ORCID ProfileRalph S. Baric5, View ORCID ProfileGalit Alter6,9, View ORCID ProfilePeter K. Sorger3, View ORCID ProfileJacob D. Estes4, View ORCID ProfileHanne Andersen7, View ORCID ProfileMark G. Lewis7, View ORCID ProfileDan H. Barouch1,6,9,† See all authors and affiliations Science 20 May 2020: eabc4776 DOI: 10.1126/science.abc4776 Abstract An understanding of protective immunity to SARS-CoV-2 is critical for vaccine and public health strategies aimed at ending the global COVID-19 pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against re-exposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. Following initial viral clearance, animals were rechallenged with SARS-CoV-2 and showed 5 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa compared with primary infection. Anamnestic immune responses following rechallenge suggested that protection was mediated by immunologic control. These data show that SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates.
    128浏览量
    原文链接

  • 《Nature，6月9日，Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-10
    • Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Brandi N. Williamson, Friederike Feldmann, Benjamin Schwarz, Kimberly Meade-White, Danielle P. Porter, Jonathan Schulz, Neeltje van Doremalen, Ian Leighton, Claude Kwe Yinda, Lizzette Pérez-Pérez, Atsushi Okumura, Jamie Lovaglio, Patrick W. Hanley, Greg Saturday, Catharine M. Bosio, Sarah Anzick, Kent Barbian, Tomas Cihlar, Craig Martens, Dana P. Scott, Vincent J. Munster & Emmie de Wit Nature (2020) Abstract Effective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2, that is currently investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4. In animal models, remdesivir treatment was effective against MERS-CoV and SARS-CoV infection.2,5,6 In vitro, remdesivir inhibited replication of SARS-CoV-2.7,8 Here, we investigated the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection9. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages 12hrs after the first treatment administration. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment.
    75浏览量
    原文链接